What's in Store for These 5 Medical Companies This Earnings Season?

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Zacks Investment Research • Feb 23, 2026

Ironwood vs. Bausch Health: Which GI Drug Stock is a Better Pick Now?

IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.

Zacks Investment Research • Feb 20, 2026

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its fourth quarter and full year 2025 investor update conference call and webcast at 8:30 a.m. Eastern Time on Wednesday, February 25, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 8188306. To access the webcast, please visit the Investors & Media section o.

Business Wire • Feb 18, 2026

IRWD Rises 307% in 6 Months: Is This an Indication to Buy the Stock?

Ironwood surges 307% in six months on rising Linzess demand and an upbeat 2026 revenue outlook. The company is also making good pipeline progress.

Zacks Investment Research • Feb 12, 2026

3 Stocks Trading Near $5 With Massive Earnings Upside

Contrary to what investors have seen this earnings season, earnings growth is traditionally one of the key indicators of stock price growth. For calendar year 2026, FactSet forecasts earnings growth of companies in the S&P 500 to come in at 15%.

MarketBeat • Feb 8, 2026

Does Ironwood's Bullish 2026 View Signal Greater Linzess Adoption?

IRWD expects Linzess demand to accelerate, driving a bullish 2026 outlook with revenue growth, higher profits and expanding adoption.

Zacks Investment Research • Feb 5, 2026

4 Stocks Trading Near 52-Week High With More Upside Potential

Stocks like IPGP, DG, IRWD and SAIC are seeing price strength and have a high chance of carrying the momentum forward.

Zacks Investment Research • Jan 23, 2026

Ironwood Pharmaceuticals' 2026 Guidance Shock Sparks a Major Re-Rating

The pharmaceutical sector is famously volatile, usually driven by the binary outcomes of clinical trials. A drug either works, sending the stock to the moon, or it fails, causing a crash.

MarketBeat • Jan 7, 2026

5 Small Drug Stocks to Buy as Industry Recovery Picks Up

Innovation is at its peak in the Zacks Medical-Drugs industry. SLNO, NKTR, RIGL, IRWD and MRKR may prove to be good additions to one's portfolio.

Zacks Investment Research • Jan 7, 2026

Ironwood Stock Rises 27% on Upbeat Revenue Guidance for 2026

IRWD shares jump on upbeat 2026 revenue guidance amid rising Linzess demand in the United States. The company also provides a key pipeline update.

Zacks Investment Research • Jan 5, 2026